Castle Biosciences Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Castle Biosciences has an operating margin of 2.6%, meaning the company retains $3 of operating profit per $100 of revenue. This below-average margin results in a low score of 13/100, suggesting thin profitability after operating expenses. This is up from -30.9% the prior year.
Castle Biosciences's revenue surged 51.1% year-over-year to $332.1M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Castle Biosciences carries a low D/E ratio of 0.02, meaning only $0.02 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 7.29, Castle Biosciences holds $7.29 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Castle Biosciences has a free cash flow margin of 11.0%, earning a moderate score of 55/100. The company generates positive cash flow after capital investments, but with room for improvement.
Castle Biosciences generates a 4.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 16/100.
Castle Biosciences scores 8.55, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($967.6M) relative to total liabilities ($75.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Castle Biosciences passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Castle Biosciences generates $3.56 in operating cash flow ($64.9M OCF vs $18.2M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Castle Biosciences earns $15.0 in operating income for every $1 of interest expense ($8.7M vs $577K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
This page shows Castle Biosciences (CSTL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Castle Biosciences generated $332.1M in revenue in fiscal year 2024. This represents an increase of 51.1% from the prior year.
Castle Biosciences's EBITDA was $24.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 144.3% from the prior year.
Castle Biosciences generated $36.5M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 289.8% from the prior year.
Castle Biosciences reported $18.2M in net income in fiscal year 2024. This represents an increase of 131.7% from the prior year.
Castle Biosciences earned $0.62 per diluted share (EPS) in fiscal year 2024. This represents an increase of 129.0% from the prior year.
Castle Biosciences held $119.7M in cash against $9.7M in long-term debt as of fiscal year 2024.
Castle Biosciences paid $0.00 per share in dividends in fiscal year 2024.
Castle Biosciences had 28M shares outstanding in fiscal year 2024. This represents an increase of 3.9% from the prior year.
Castle Biosciences's gross margin was 81.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 2.3 percentage points from the prior year.
Castle Biosciences's operating margin was 2.6% in fiscal year 2024, reflecting core business profitability. This is up 33.5 percentage points from the prior year.
Castle Biosciences's net profit margin was 5.5% in fiscal year 2024, showing the share of revenue converted to profit. This is up 31.6 percentage points from the prior year.
Castle Biosciences's ROE was 4.0% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.
Castle Biosciences invested $52.0M in research and development in fiscal year 2024. This represents a decrease of 2.9% from the prior year.
Castle Biosciences invested $28.3M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 108.0% from the prior year.
CSTL Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $83.0M-3.6% | $86.2M-2.0% | $88.0M+1.9% | $86.3M-0.8% | $87.0M+19.2% | $73.0M+10.4% | $66.1M+7.5% | $61.5M |
| Cost of Revenue | $18.7M+6.1% | $17.6M+7.6% | $16.4M+1.2% | $16.2M+11.5% | $14.5M+4.5% | $13.9M+11.8% | $12.4M+9.8% | $11.3M |
| Gross Profit | $64.3M-6.2% | $68.6M-4.2% | $71.6M+2.1% | $70.1M-3.2% | $72.5M+22.7% | $59.1M+10.0% | $53.7M+7.0% | $50.2M |
| R&D Expenses | $13.0M+1.4% | $12.8M+1.6% | $12.6M+6.9% | $11.8M-16.7% | $14.1M+2.4% | $13.8M+6.3% | $13.0M+0.5% | $12.9M |
| SG&A Expenses | $55.9M-3.7% | $58.1M-0.9% | $58.6M+17.3% | $50.0M-2.2% | $51.1M+5.3% | $48.5M+10.0% | $44.1M-1.2% | $44.6M |
| Operating Income | -$6.8M-60.1% | -$4.3M+84.8% | -$27.9M-789.6% | $4.0M-19.2% | $5.0M+191.6% | -$5.5M+3.3% | -$5.7M+41.3% | -$9.6M |
| Interest Expense | $24K+166.7% | $9K+12.5% | $8K-94.9% | $157K-27.3% | $216K+1700.0% | $12K+500.0% | $2K0.0% | $2K |
| Income Tax | $115K+102.5% | -$4.7M-1003.1% | -$423K+75.2% | -$1.7M-64.9% | -$1.0M-2397.8% | $45K+15.4% | $39K+21.9% | $32K |
| Net Income | -$501K-111.1% | $4.5M+117.5% | -$25.8M-369.5% | $9.6M+7.5% | $8.9M+452.0% | -$2.5M+1.8% | -$2.6M+62.6% | -$6.9M |
| EPS (Diluted) | $-0.02-113.3% | $0.15+116.7% | $-0.90-381.3% | $0.32+3.2% | $0.31+444.4% | $-0.09-12.5% | $-0.08+69.2% | $-0.26 |
CSTL Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $562.8M+3.3% | $544.7M+8.6% | $501.7M-5.6% | $531.2M+9.0% | $487.3M+6.3% | $458.5M+1.1% | $453.3M+4.0% | $436.0M |
| Current Assets | $357.6M+2.6% | $348.7M-0.2% | $349.4M-3.0% | $360.2M+12.4% | $320.4M+8.3% | $295.8M0.0% | $295.6M+5.7% | $279.6M |
| Cash & Equivalents | $85.6M+4.0% | $82.2M-8.3% | $89.7M-25.1% | $119.7M+39.9% | $85.6M+3.2% | $82.9M-16.1% | $98.8M+8.4% | $91.2M |
| Inventory | $8.7M+3.4% | $8.4M+22.1% | $6.8M-15.8% | $8.1M+1.5% | $8.0M+4.8% | $7.6M-3.7% | $7.9M+37.7% | $5.8M |
| Accounts Receivable | $49.5M-5.4% | $52.3M-7.2% | $56.4M+10.0% | $51.2M+11.4% | $46.0M+7.7% | $42.7M+11.5% | $38.3M+3.5% | $37.0M |
| Goodwill | $10.7M0.0% | $10.7M0.0% | $10.7M0.0% | $10.7M0.0% | $10.7M0.0% | $10.7M0.0% | $10.7M0.0% | $10.7M |
| Total Liabilities | $95.7M+7.1% | $89.4M+45.5% | $61.4M-18.6% | $75.4M+18.9% | $63.4M+13.2% | $56.0M-9.7% | $62.1M+23.6% | $50.2M |
| Current Liabilities | $55.3M+8.7% | $50.9M+36.5% | $37.3M-24.5% | $49.4M+25.2% | $39.5M+23.5% | $32.0M-33.0% | $47.7M+31.2% | $36.3M |
| Long-Term Debt | $10.0M+24.1% | $8.1M-9.2% | $8.9M-8.5% | $9.7M-2.6% | $10.0M+0.1% | $10.0M | $0 | N/A |
| Total Equity | $467.0M+2.6% | $455.4M+3.4% | $440.3M-3.4% | $455.8M+7.5% | $423.9M+5.3% | $402.5M+2.9% | $391.3M+1.4% | $385.8M |
| Retained Earnings | -$222.0M-0.2% | -$221.5M+2.0% | -$226.0M-12.9% | -$200.1M+5.6% | -$212.0M+4.0% | -$220.9M-1.2% | -$218.4M-1.2% | -$215.8M |
CSTL Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $22.6M+8.7% | $20.8M+444.9% | -$6.0M-124.8% | $24.4M+1.5% | $24.0M+451.1% | -$6.8M-136.8% | $18.6M+270.8% | $5.0M |
| Capital Expenditures | $14.8M+60.1% | $9.3M+95.4% | $4.7M-37.4% | $7.6M+44.7% | $5.2M-42.9% | $9.2M+141.3% | $3.8M+54.5% | $2.5M |
| Free Cash Flow | $7.8M-32.5% | $11.6M+207.3% | -$10.8M-164.2% | $16.8M-10.5% | $18.8M+217.4% | -$16.0M-208.1% | $14.8M+478.6% | $2.6M |
| Investing Cash Flow | -$18.4M+35.2% | -$28.4M-26.5% | -$22.4M-488.8% | $5.8M+126.9% | -$21.4M-8.7% | -$19.7M-156.8% | -$7.7M+21.0% | -$9.7M |
| Financing Cash Flow | -$919K-1009.9% | $101K+106.5% | -$1.6M+71.2% | -$5.4M-12921.4% | $42K-99.6% | $10.6M+422.8% | -$3.3M-7426.7% | $45K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CSTL Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.5%-2.1pp | 79.5%-1.8pp | 81.4%+0.1pp | 81.3%-2.1pp | 83.3%+2.3pp | 81.0%-0.3pp | 81.2%-0.4pp | 81.6% |
| Operating Margin | -8.2%-3.3pp | -4.9%+26.8pp | -31.7%-36.4pp | 4.7%-1.1pp | 5.8%+13.3pp | -7.5%+1.1pp | -8.6%+7.1pp | -15.7% |
| Net Margin | -0.6%-5.8pp | 5.3%+34.6pp | -29.4%-40.5pp | 11.1%+0.9pp | 10.3%+13.7pp | -3.5%+0.4pp | -3.9%+7.3pp | -11.2% |
| Return on Equity | N/A | 1.0% | N/A | 2.1%0.0pp | 2.1% | N/A | N/A | N/A |
| Return on Assets | -0.1%-0.9pp | 0.8%+6.0pp | -5.1%-7.0pp | 1.8%-0.0pp | 1.8%+2.4pp | -0.5%+0.0pp | -0.6%+1.0pp | -1.6% |
| Current Ratio | 6.47-0.4 | 6.85-2.5 | 9.37+2.1 | 7.29-0.8 | 8.12-1.1 | 9.25+3.1 | 6.20-1.5 | 7.70 |
| Debt-to-Equity | 0.020.0 | 0.020.0 | 0.020.0 | 0.020.0 | 0.020.0 | 0.02+0.0 | 0.00-0.1 | 0.13 |
| FCF Margin | 9.4%-4.0pp | 13.4%+25.7pp | -12.3%-31.7pp | 19.5%-2.1pp | 21.6%+43.5pp | -21.9%-44.3pp | 22.4%+18.2pp | 4.2% |
Similar Companies
Frequently Asked Questions
What is Castle Biosciences's annual revenue?
Castle Biosciences (CSTL) reported $332.1M in total revenue for fiscal year 2024. This represents a 51.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Castle Biosciences's revenue growing?
Castle Biosciences (CSTL) revenue grew by 51.1% year-over-year, from $219.8M to $332.1M in fiscal year 2024.
Is Castle Biosciences profitable?
Yes, Castle Biosciences (CSTL) reported a net income of $18.2M in fiscal year 2024, with a net profit margin of 5.5%.
What is Castle Biosciences's earnings per share (EPS)?
Castle Biosciences (CSTL) reported diluted earnings per share of $0.62 for fiscal year 2024. This represents a 129.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Castle Biosciences's EBITDA?
Castle Biosciences (CSTL) had EBITDA of $24.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Castle Biosciences have?
As of fiscal year 2024, Castle Biosciences (CSTL) had $119.7M in cash and equivalents against $9.7M in long-term debt.
What is Castle Biosciences's gross margin?
Castle Biosciences (CSTL) had a gross margin of 81.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Castle Biosciences's operating margin?
Castle Biosciences (CSTL) had an operating margin of 2.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Castle Biosciences's net profit margin?
Castle Biosciences (CSTL) had a net profit margin of 5.5% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Castle Biosciences's return on equity (ROE)?
Castle Biosciences (CSTL) has a return on equity of 4.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Castle Biosciences's free cash flow?
Castle Biosciences (CSTL) generated $36.5M in free cash flow during fiscal year 2024. This represents a 289.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Castle Biosciences's operating cash flow?
Castle Biosciences (CSTL) generated $64.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Castle Biosciences's total assets?
Castle Biosciences (CSTL) had $531.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Castle Biosciences's capital expenditures?
Castle Biosciences (CSTL) invested $28.3M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Castle Biosciences spend on research and development?
Castle Biosciences (CSTL) invested $52.0M in research and development during fiscal year 2024.
How many shares does Castle Biosciences have outstanding?
Castle Biosciences (CSTL) had 28M shares outstanding as of fiscal year 2024.
What is Castle Biosciences's current ratio?
Castle Biosciences (CSTL) had a current ratio of 7.29 as of fiscal year 2024, which is generally considered healthy.
What is Castle Biosciences's debt-to-equity ratio?
Castle Biosciences (CSTL) had a debt-to-equity ratio of 0.02 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Castle Biosciences's return on assets (ROA)?
Castle Biosciences (CSTL) had a return on assets of 3.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Castle Biosciences's Altman Z-Score?
Castle Biosciences (CSTL) has an Altman Z-Score of 8.55, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Castle Biosciences's Piotroski F-Score?
Castle Biosciences (CSTL) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Castle Biosciences's earnings high quality?
Castle Biosciences (CSTL) has an earnings quality ratio of 3.56x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Castle Biosciences cover its interest payments?
Castle Biosciences (CSTL) has an interest coverage ratio of 15.0x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Castle Biosciences?
Castle Biosciences (CSTL) scores 64 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.